EUVIMEDEUVIMED entdecken
Crossref

Effectiveness and Safety of Off-label Tofacitinib Use for Atopic Dermatitis, Alopecia Areata and Plaque Psoriasis: An Observational Study

Saumya Panda, Titas Panda, Shreya Kotal, Suparna Chatterjee

Indian Journal of Dermatology · 30.10.2026

DOI: 10.4103/ijd.ijd_948_25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Dermatology, online erschienen am 30.10.2026. Verfasst von Saumya Panda und 3 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tofacitinib is a first-generation janus kinase inhibitor approved for rheumatoid arthritis, psoriatic arthritis and ulcerative colitis. However, it is also used for several off-label dermatological disorders. Aims and Objectives: To evaluate the effectiveness and safety of off-label use of tofacitinib in alopecia areata, plaque psoriasis and atopic dermatitis. Materials and Methods: This prospective observational study was conducted at a tertiary care hospital. Patients either currently taking tofacitinib for ≤2 weeks or being prescribed the drug for atopic dermatitis (AD), alopecia areata (AA) and plaque psoriasis (PP) were included. Socio-demographic profile, tofacitinib and other drug details were noted. Disease severity scores—SALT (Severity of Alopecia Tool) for AA, PASI (Psoriasis Area and Severity Index) for PP and SCORAD (SCORing Atopic Dermatitis) for AD patients—were recorded at enrolment and at 2, 4 and 8 ± 2 weeks’ visits, respectively. Investigators’ Global Assessment (IGA) and all treatment-emergent adverse effects were also assessed.

Results

Thirty patients (13-AA; 9-PP; 8-AD) were enrolled. All were on 5 mg twice daily tofacitinib during the study course. At 8 ± 2 weeks, 13 cases (100%), 9 cases (77.77%), 8 cases (62.5%) and 30 cases (30%) achieved > 50% reduction in SALT, PASI, SCORAD and IGA, respectively. There were statistically significant differences between baseline and the follow-up visits in all disease severity scores, indicating significant clinical improvement. Twelve non-serious adverse drug reactions were noted, which resolved with symptomatic treatment and did not require drug discontinuation.

Conclusion

This study generated data to guide clinicians regarding the off-label use of tofacitinib, as it showed promising results with few non-serious adverse effects.

Zitieren

APA

Panda, S., Panda, T., Kotal, S., & Chatterjee, S. (2026). Effectiveness and Safety of Off-label Tofacitinib Use for Atopic Dermatitis, Alopecia Areata and Plaque Psoriasis: An Observational Study. Indian Journal of Dermatology. https://doi.org/10.4103/ijd.ijd_948_25

Vancouver

Panda S, Panda T, Kotal S, Chatterjee S. Effectiveness and Safety of Off-label Tofacitinib Use for Atopic Dermatitis, Alopecia Areata and Plaque Psoriasis: An Observational Study. Indian Journal of Dermatology. 2026. doi:10.4103/ijd.ijd_948_25

BibTeX
@article{Panda2026,
  author = {Panda, Saumya and Panda, Titas and Kotal, Shreya and Chatterjee, Suparna},
  title = {Effectiveness and Safety of Off-label Tofacitinib Use for Atopic Dermatitis, Alopecia Areata and Plaque Psoriasis: An Observational Study},
  journal = {Indian Journal of Dermatology},
  year = {2026},
  doi = {10.4103/ijd.ijd_948_25}
}
Kostenlos starten →